October 2019
Volume 5, Issue 12
This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.
Table of Contents
October 2019 Issue
A Leiden Wild Card
In our August 2019 issue, Leslie J. Raffini, MD, responded to a colleague seeking advice on managing large venous thromboembolisms (VTEs) in two teenaged...
Trigger Warning
In our August 2019 issue, two hematologists debated whether gun violence should be considered a public health issue and, by extension, whether physicians should...
Fathers (and Mothers) of Hematology
In 1963, Boston hematologist William Dameshek wrote an essay in the journal he’d founded 17 years earlier, Blood, describing 18th-century English anatomist William Hewson’s detailed...
October 2019 Issue
ASH Clinical News Now Available on the ASH Publications App, ABIM Changing Maintenance of...
ASH Clinical News Now Available on the ASH Publications App
The American Society of Hematology (ASH) Publications app provides access to content from Blood, Blood...
Remembering Stanley Schrier, John Hansen, and more
Remembering Stanley Schrier (1929 – 2019)
Stanley Schrier, MD, a former American Society of Hematology (ASH) president who spent nearly 60 years at Stanford University’s...
October 2019 Issue
The Other Opioid Epidemic
Federal crackdowns on opioid prescribing have shifted the crisis from overdoses to undertreatment
The United States is in the grip of an opioid epidemic that...
Pulling Back the Curtain: Robert A. Kyle, MD
In this edition, Robert A. Kyle, MD, chronicles his nearly 70-year career and rural beginnings, from attending a one-room schoolhouse in North Dakota to...
More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma
As part of the 2019 ASH Meeting on Hematologic Malignancies held September 6-7 in Chicago, experts were invited to discuss challenging patient care questions,...
October 2019 Issue
Reader Responses: How would you treat a patient with a prolonged PTT and antiphospholipid...
Here’s how readers responded to a You Make the Call question about a patient with a prolonged PTT and antiphospholipid antibodies.
Disclaimer: ASH does not...
How would you treat a patient with a prolonged PTT and antiphospholipid antibodies?
This month, Caroline Berube, MD, discusses treatment for a patient with a prolonged PTT and antiphospholipid antibodies.
And don't forget to check out next month's...
October 2019 Issue
Pretransplant Bridging With Blinatumomab Reduces MRD in Children With B-Cell Acute Lymphocytic Leukemia
In a study of children with B-cell acute lymphocytic leukemia (B-ALL) who are about to undergo allogeneic hematopoietic cell transplantation (alloHCT), bridging with blinatumomab...
Pegylated Interferon Leads to High Response Rates in Essential Thrombocythemia and Polycythemia Vera After...
According to results of a phase II study published in Blood, treatment with pegylated-interferon-α (PEG-rIFN-α) was associated with an overall response rate (ORR) of...
FDA Approves Ferric Maltol for Treatment of Iron Deficiency
The U.S. Food and Drug Administration (FDA) announced its approval of oral ferric maltol for the treatment of iron deficiency in adults.
Ferric maltol is...
Clofarabine Plus Cytarabine May Provide Less Toxic Option for Newly Diagnosed Pediatric Patients With...
For children newly diagnosed with acute myeloid leukemia (AML), treatment with a combination of clofarabine plus cytarabine was associated with similar survival rates when...
Rivipansel Fails to Meet Phase III Trial Endpoints
In a pivotal phase III trial, rivipansel failed to meet its primary and secondary efficacy endpoints in patients with sickle cell disease (SCD) who...
Can ICH Survivors Safely RESTART Antiplatelet Therapy?
While treatment with antiplatelet therapy lessens the risks of subsequent occlusive vascular events, it may increase the risk of recurrent intracerebral hemorrhage (ICH) in...
Roxadustat Improves Hemoglobin Levels and Response Rates in Patients With Anemia Related to Chronic...
According to results from a phase III trial, roxadustat increased hemoglobin levels and hemoglobin response rates, compared with placebo, in patients with anemia and...
Genetic Testing and Drug Companies Partner to Develop New Medicines
Since its launch, 23andMe has provided more than 8 million customers with information about their ancestry and predisposition to developing certain diseases. Now, a...
CMS Increases Payment, Access to CAR T-Cell Therapy
The Centers for Medicare and Medicaid Services (CMS) announced two policy changes that should improve access to chimeric antigen receptor (CAR) T-cell therapies: First,...
Textured Breast Implants Recalled by FDA Over Cancer Risk
The U.S. Food and Drug Administration (FDA) has requested that pharmaceutical company Allergan recall its BIOCELL textured breast implants due to a risk of...
October 2019 Issue
Two Studies Support Using Concizumab as Prophylaxis in Patients With Hemophilia
Concizumab could be a safe and effective subcutaneous prophylactic treatment option for patients with hemophilia A or B with or without inhibitors, according to...
Hemophilia B: The Next Target for Gene Therapy?
Treatment with a single dose of AMT-061, an investigational gene therapy, led to increased factor IX (FIX) activity and reduced spontaneous bleeding episodes for...
From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
